Non-Hodgkin Lymphoma

Tafasitamab plus lenalidomide/rituximab cut progression risk by over 50% in relapsed follicular lymphoma, supporting its approval as a key second-line option.

The FDA granted RMAT designation to MB-105 for CD5-positive relapsed/refractory T-cell lymphoma.

Pule Wang, MD, discusses safety data with CNS bridging radiotherapy before CAR T in B-cell lymphoma.

In the phase 1 ANTLER study, vispa-cel demonstrated ORRs of 82% and 86% among patients in the confirmatory and optimized cohorts, respectively.

The removal of REMS programs for approved CAR T-cell therapies could enable improved access and streamlined management of hematologic malignancies.

A Data Monitoring Committee confirmed that the safety profile of HyBryte is acceptable and that the agent is not associated with safety concerns in CTCL.

A mogamulizumab-based combination led to complete remission in a patient with CAR-positive T-cell lymphoma with CCR4 overexpression.

Here is your Q4 2025 preview spotlighting 10 FDA decisions to watch, including upcoming PDUFAs for belantamab mafodotin, revumenib, sevabertinib, and more.

Multiple myeloma and non-Hodgkin lymphoma emerge as key hematology topics ahead of ESMO 2025, followed by MPNs and T-cell lymphoma.

Saurabh Dahiya, MD, FACP, discusses the unique mechanism of action of the CD19/CD20–targeting CAR T-cell therapy in relapsed/refractory LBCL.

Julie M. Vose, MD, MBA, discusses the safety profile of epcoritamab in patients with relapsed/refractory LBCL who have achieved a 2-year complete response.

A preview of the hematologic oncology abstracts and presentations to watch at the 2025 ESMO Congress in Berlin.

Saurabh Dahiya, MD, FACP, discussed how the unique mechanism of action of KITE-363 may improve upon the efficacy of other CAR T-cell therapies for LBCL.

The CHMP has recommended the European approval of subcutaneous mosunetuzumab in relapsed/refractory follicular lymphoma.

Orelabrutinib has been approved as a treatment option for patients with marginal zone lymphoma in Singapore.

A chemotherapy-free regimen of mosunetuzumab and polatuzumab vedotin improved PFS and response rates vs R-GemOx in relapsed/refractory LBCL.

Treatment with mosunetuzumab plus polatuzumab vedotin yielded high response rates and had a manageable safety profile in BTK inhibitor–exposed MCL.

Loncastuximab tesirine plus glofitamab demonstrated early promise in patients with relapsed or refractory large B-cell lymphoma.

Here is your guide to all therapeutic options that were cleared by the FDA in August 2025 spanning tumor types.

The top 5 OncLive videos of the week cover insights in polycythemia vera, multiple myeloma, colorectal cancer, LBCL, and mantle cell lymphoma.

Glofitamab plus GemOx received approval in Canada for patients with relapsed or refractory DLBCL not otherwise specified who are not eligible for ASCT.

The European approval of a zanubrutinb tablet formulation covers indications in CLL, Waldenström macroglobulinemia, MZL, and follicular lymphoma.

The top 5 OncLive videos of the week cover insights in MCL, prostate cancer, plexiform neurofibromas, breast cancer, and follicular lymphoma.

Retrospective data showed CAR T-cell therapy is feasible in patients with aggressive lymphomas and active autoimmune diseases.